Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. 2018

Abhilash Koratala, and Xu Zeng
Division of Nephrology, Hypertension and Renal Transplantation University of Florida Gainesville Florida.

Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV-related vasculitis and may evade the need for dialysis as in our patient.

UI MeSH Term Description Entries

Related Publications

Abhilash Koratala, and Xu Zeng
January 1993, American journal of nephrology,
Abhilash Koratala, and Xu Zeng
March 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Abhilash Koratala, and Xu Zeng
March 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Abhilash Koratala, and Xu Zeng
May 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Abhilash Koratala, and Xu Zeng
January 2015, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
Abhilash Koratala, and Xu Zeng
April 2015, Transplant infectious disease : an official journal of the Transplantation Society,
Abhilash Koratala, and Xu Zeng
December 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!